Avacta Group


Market Cap-355.1m

Last Close -142.5

Avacta is focused on the development of its Affimer technology for use in therapeutic and diagnostic/reagent applications. Assets include AVA004 (PD-L1), AVA021 (PD-L1/LAG-3) and AVA004/100 (PD-L1/I-DASH).

More Avacta Group content >

Investment summary

Avacta has announced a joint venture with Daewoong Pharmaceuticals to develop mesenchymal stem cell (MSC) therapies incorporating Affimers. The joint venture (JV), will be based in South Korea and entirely funded by Daewoong with Avacta providing no financial investment. Avacta will develop Affimers (and be reimbursed by Daewoong for all research and development costs) for several undisclosed targets in inflammatory and autoimmune disorders. Avacta will have a 45% shareholding in the new company, will not contribute financially to the JV, and will retain the rights to any Affimers developed for the JV outside of their use in engineered cell therapies. We do not currently include the JV in our valuation due to its early nature; however, we view the deal positively and will reassess as work progresses. We retain our valuation of Avacta at £47m.

Y/E Dec
Revenue (£m)
PBT (£m)
EPS (fd) (p)
P/E (x)
P/CF (x)
2017A 2.7 N/A (7.9) (9.8) N/A N/A
2018A 2.8 N/A (10.4) (13.5) N/A N/A
2019E 4.5 N/A (11.1) (8.1) N/A N/A
2020E 4.5 N/A (12.7) (9.3) N/A N/A
Content on Avacta Group
Avacta Group – New JV gives further validation to Affimers
Healthcare | Flash note | 8 January 2020
Executive interview – Avacta Group
Healthcare | Edison TV | 5 December 2019
View more
Register to receive research on Avacta Group as it is published
Share price graph
Balance sheet
Forecast net cash (£m) 5.7
Forecast gearing ratio (%) N/A
Price performance
Actual 6.9 143.5 423.4
Relative* 7.7 125.2 519.7
52-week high/low 202.0p/14.0p
*% relative to local index
Key management
Alastair Smith CEO
Tony Gardiner CFO